Skip to main content
. 2015 Sep 21;10(12):2687–2696. doi: 10.1021/acschembio.5b00655

Figure 2.

Figure 2

Comparative analysis of compound 1 and dasatinib. (A) DDR2 was transiently expressed in 293T cells by the pCMV6 expression vector. Cells were treated with depicted concentrations of compound 1 or dasatinib. Cell lysates were immunoprecipitated with anti-DDR2, followed by Western blotting with anti-DDR2 or antiphosphotyrosine. (B) Proliferation of NCI-H2286 and HCC-366 grown for 5 days in the presence of compound 1 or dasatinib. Graph shows mean ± SD from a single experiment representative of three independent experiments with three replicates per treatment per experiment. (C) Effects of dasatinib and compound 1 treatment on p-SFK levels in NCI-H2286 and HCC-366. Cells were treated for 3 h with 0.5 μM of each drug.